GlassScriptPhysician profile
Daniel Bernard Groblewski
NPI 1821179888
$10,165.77
in general payments reported to CMS, 2019-2025
52 companies · $14.81 in 2025
The $14.81 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,427 · 2020: $2,412 · 2021: $2,197 · 2022: $2,253 · 2023: $646 · 2024: $216 · 2025: $14.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $758 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $758.21 |
| Education | $118.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $853.89 | 2019-2023 | |
| Amgen INC. | $810.38 | 2019-2023 | Aimovig |
| Emd Serono, INC. | $787.66 | 2019-2023 | Mavenclad |
| Mdd US Operations, LLC | $765.33 | 2019-2022 | |
| Abbvie INC. | $733.31 | 2021-2023 | |
| Biogen, INC. | $618.24 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $546.61 | 2019-2023 | Austedo |
| Kyowa Kirin, INC. | $487.60 | 2019-2023 | Nourianz |
| Alexion Pharmaceuticals, INC. | $441.82 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $436.68 | 2019-2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $391.49 | 2019-2022 | |
| Sk Life Science, INC. | $347.44 | 2020-2022 | |
| Adamas Pharmaceuticals, INC. | $323.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $286.97 | 2019-2021 | |
| Allergan, INC. | $264.20 | 2019-2020 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Groblewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.